Pro Ultrshrt Health Care
RXD----
Pfizer sees strong response for pediatric pneumonia vaccine in mid-stage trial
Seeking Alpha·- Pfizer announced phase 2 trial data for its pediatric 25-valent pneumococcal conjugate vaccine candidate, PF-07872412. - The study involving ~400 infants showed a robust immune response against all 25 serotypes after a four-dose series. - The vaccine demonstrated a safety and tolerability profile similar to Prevnar 20, with mostly mild to moderate local reactions.